New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareOrforglipron vs Oxytocin

Orforglipron vs Oxytocin

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Orforglipron
Cognitive EnhancementSexual Health & Libido
Oxytocin
Summary
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
Oxytocin is a 9-amino acid neuropeptide produced in the hypothalamus with diverse roles in social bonding, trust, stress reduction, and sexual function. Exogenous administration is used therapeutically to improve social cognition, reduce anxiety, and enhance intimacy.
Half-Life
~12 hours (once-daily oral dosing)
~3–5 minutes (IV); ~30–60 minutes (intranasal, CNS effects persist longer)
Admin Route
Oral
Intranasal, SubQ, IV
Research
Typical Dose
12 mg → 24 mg → 36 mg → 45 mg
20–40 IU
Frequency
Once daily
As needed (not daily long-term)
Key Benefits
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
  • Enhances social bonding and trust
  • Reduces social anxiety and fear of rejection
  • Improves autism spectrum symptoms (social cognition)
  • Reduces cortisol and stress reactivity
  • Enhances sexual arousal and intimacy
  • Promotes maternal behavior and bonding
  • May improve depressive symptoms
  • Appetite suppression and metabolic effects
Side Effects
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
  • Mild uterine cramping (avoid in pregnancy)
  • Nasal irritation (intranasal)
  • Headache
  • Potential emotional over-attachment or jealousy amplification
  • +2 more
Stacks With